Report Detail

Pharma & Healthcare Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review

  • RnM3436005
  • |
  • 20 May, 2019
  • |
  • Global
  • |
  • 59 Pages
  • |
  • GlobalData
  • |
  • Pharma & Healthcare

Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Jazz Pharmaceuticals plc (Jazz Pharmaceuticals) is a specialty biopharmaceutical company which identifies, develops and commercializes medicines with focus on narcolepsy, cancer, pain and psychiatry. Its major marketed products include Xyrem, sodium oxybate oral solution, for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze, an asparagine specific enzyme, for acute lymphoblastic leukemia; Prialt, ziconotide, for severe chronic pain in patients who are intolerant or refractory to other treatments and FazaClo orally disintegrating clozapine tablets indicated for the treatment of resistant schizophrenia. The company sells its products through a network of local distributors and wholesalers. It has operations in the US and Europe. Jazz Pharmaceuticals is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals Plc Key Recent Developments

May 07,2019 Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results
Apr 08,2019 Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe
Feb 26,2019 Jazz Pharmaceuticals announces full year and fourth quarter 2018 financial results
Feb 14,2019 Jazz Pharmaceuticals announces appointment of Anne O'Riordan to its board of directors

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Table of Contents

    Table of Contents

      List of Tables

        List of Figures

          Section 1 - About the Company

            Jazz Pharmaceuticals Plc - Key Facts

              Jazz Pharmaceuticals Plc - Key Employees

                Jazz Pharmaceuticals Plc - Key Employee Biographies

                  Jazz Pharmaceuticals Plc - Major Products and Services

                    Jazz Pharmaceuticals Plc - History

                      Jazz Pharmaceuticals Plc - Company Statement

                        Jazz Pharmaceuticals Plc - Locations And Subsidiaries

                          Head Office

                            Other Locations & Subsidiaries

                              Section 2 – Company Analysis

                                Company Overview

                                  Jazz Pharmaceuticals Plc - Business Description

                                    Product Category: Defitelio/defibrotide

                                      Overview

                                        Performance

                                          Product Category: Erwinaze/Erwinase

                                            Overview

                                              Performance

                                                Product Category: Other

                                                  Overview

                                                    Product Category: Other Products

                                                      Performance

                                                        Product Category: Prialt (ziconotide) Intrathecal Infusion

                                                          Overview

                                                            Performance

                                                              Product Category: Vyxeos

                                                                Overview

                                                                  Performance

                                                                    Product Category: Xyrem

                                                                      Overview

                                                                        Performance

                                                                          Product Category: Net Product Sales

                                                                            Performance

                                                                              Product Category: Royalties and Contract Revenue

                                                                                Performance

                                                                                  Geographical Segment: All Other

                                                                                    Performance

                                                                                      Geographical Segment: Europe

                                                                                        Performance

                                                                                          Geographical Segment: The US

                                                                                            Performance

                                                                                              R&D Overview

                                                                                                Jazz Pharmaceuticals Plc - Corporate Strategy

                                                                                                  Jazz Pharmaceuticals Plc - SWOT Analysis

                                                                                                    SWOT Analysis - Overview

                                                                                                      Jazz Pharmaceuticals Plc - Strengths

                                                                                                        Jazz Pharmaceuticals Plc - Weaknesses

                                                                                                          Jazz Pharmaceuticals Plc - Opportunities

                                                                                                            Jazz Pharmaceuticals Plc - Threats

                                                                                                              Jazz Pharmaceuticals Plc - Key Competitors

                                                                                                                Section 3 – Company Financial Ratios

                                                                                                                  Financial Ratios - Capital Market Ratios

                                                                                                                    Financial Ratios - Annual Ratios

                                                                                                                      Performance Chart

                                                                                                                        Financial Performance

                                                                                                                          Financial Ratios - Interim Ratios

                                                                                                                            Financial Ratios - Ratio Charts

                                                                                                                              Section 4 – Company’s Lifesciences Financial Deals and Alliances

                                                                                                                                Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019

                                                                                                                                  Jazz Pharmaceuticals Plc, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019

                                                                                                                                    Jazz Pharmaceuticals Plc, Recent Deals Summary

                                                                                                                                      Section 5 – Company’s Recent Developments

                                                                                                                                        May 07, 2019: Jazz Pharmaceuticals Announces First Quarter 2019 Financial Results

                                                                                                                                          Apr 08, 2019: Jazz, Alexion and Lundbeck to pay $122m to settle kickback probe

                                                                                                                                            Feb 26, 2019: Jazz Pharmaceuticals announces full year and fourth quarter 2018 financial results

                                                                                                                                              Feb 14, 2019: Jazz Pharmaceuticals announces appointment of Anne O'Riordan to its board of directors

                                                                                                                                                Jan 04, 2019: Jazz and Codiak collaborate on creating engineered exosomes for cancer

                                                                                                                                                  Nov 09, 2018: Jazz Pharmaceuticals Submits Marketing Authorization Application to European Medicines Agency for Solriamfetol as a Treatment to Improve Wakefulness and Reduce Excessive Daytime Sleepiness in Adult Patients with Narcolepsy or Obstructive Sleep Apnea

                                                                                                                                                    Nov 06, 2018: Jazz Pharmaceuticals announces third quarter 2018 financial results

                                                                                                                                                      Oct 29, 2018: Jazz Pharmaceuticals Announces FDA Approval of Xyrem (sodium oxybate) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Pediatric Narcolepsy Patients

                                                                                                                                                        Oct 08, 2018: Jazz Pharmaceuticals Undergoes Drug supply Shortage Due to Manufacturing Problems

                                                                                                                                                          Oct 01, 2018: Jazz Pharmaceuticals Survey Highlights Significant Impact of Excessive Daytime Sleepiness Related to Sleep Apnea

                                                                                                                                                            Section 6 – Appendix

                                                                                                                                                              Methodology

                                                                                                                                                                Ratio Definitions

                                                                                                                                                                  About GlobalData

                                                                                                                                                                    Contact Us

                                                                                                                                                                      Disclaimer

                                                                                                                                                                      Summary:
                                                                                                                                                                      Get latest Market Research Reports on Jazz Pharmaceuticals Plc (JAZZ) . Industry analysis & Market Report on Jazz Pharmaceuticals Plc (JAZZ) is a syndicated market report, published as Jazz Pharmaceuticals Plc (JAZZ) - Financial and Strategic SWOT Analysis Review. It is complete Research Study and Industry Analysis of Jazz Pharmaceuticals Plc (JAZZ) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                      Last updated on

                                                                                                                                                                      REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                      Purchase this Report

                                                                                                                                                                      $500.00
                                                                                                                                                                      $1,000.00
                                                                                                                                                                      $1,500.00
                                                                                                                                                                      386.50
                                                                                                                                                                      773.00
                                                                                                                                                                      1,159.50
                                                                                                                                                                      465.50
                                                                                                                                                                      931.00
                                                                                                                                                                      1,396.50
                                                                                                                                                                      76,345.00
                                                                                                                                                                      152,690.00
                                                                                                                                                                      229,035.00
                                                                                                                                                                      42,200.00
                                                                                                                                                                      84,400.00
                                                                                                                                                                      126,600.00
                                                                                                                                                                      Credit card Logo

                                                                                                                                                                      Related Reports


                                                                                                                                                                      Reason to Buy

                                                                                                                                                                      Request for Sample of this report